4/A: Castle Biosciences COO Amends Stock Sale Disclosure

Castle Biosciences' Chief Operating Officer Kristen M Oelschlager filed an amended Form 4 to correct details regarding an indirect sale of 18,007 common shares.

Summary

• Kristen M Oelschlager, Chief Operating Officer of Castle Biosciences, Inc. (CSTL), filed an amended Form 4.
• The amendment corrects an original Form 4 filed on August 29, 2025.
• The original filing incorrectly reported a direct sale of shares by the Reporting Person.
• The 18,007 shares of common stock were actually sold indirectly by The Fritz Shorter Trust on August 27, 2025.
• The shares were sold at a weighted-average price of $21.69, with trades ranging from $21.24 to $21.94.
• Following the transaction, Kristen M Oelschlager directly holds 52,924 shares of common stock.
• Following the transaction, Kristen M Oelschlager indirectly holds 100,937 shares of common stock through The Fritz Shorter Trust.
• The original Form 4 also mistakenly indicated incorrect direct and indirect share counts.
• A reconciliation determined that previously reported holdings were understated by 68 shares, and current holdings have been adjusted.
• The Reporting Person transferred 96,322 shares to The Fritz Shorter Trust on March 19, 2025, and an additional 22,622 shares on August 22, 2025.
• These transfers to the Trust did not constitute a change in beneficial ownership as the Reporting Person and her spouse are trustees and sole beneficiaries, retaining voting and investment power.

Sentiment

Score: 5

Explanation: The filing is neutral as it is a factual correction of an insider transaction, providing clarity on beneficial ownership and share counts without indicating any operational or financial performance changes for the company.

Future Outlook

This filing is an amendment to an insider transaction report and does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is a routine insider transaction amendment and does not provide information relevant to broader industry trends or competitive analysis.

Related Party Transactions

• The sale of 18,007 shares was executed by The Fritz Shorter Trust, of which the Reporting Person and her spouse are trustees and sole beneficiaries, and the Trust is revocable, meaning the Reporting Person retains voting and investment power over the shares.

Stakeholder Impact

• Shareholders: Provides clarified and accurate information regarding an insider's beneficial ownership and transaction details, ensuring transparency.

Key Dates

Keywords

CSTL, Castle Biosciences, Form 4/A, Insider Transaction, Stock Sale, Beneficial Ownership, Amendment, Chief Operating Officer